Welcome back! This week we're doing something a little different and discussing a few important studies on the ribosomal P in neuropsychiatric SLE.  We also have theme music!  Let me know what you think about both on twitter @EBRheum. 

Today we'll discuss an important trial on febuxostat (ulloric), which raises important concerns about its safety from a cardiovascular perspective. Be sure to tune in to the #RheumJC discussion that will be happening this Thursday! 

Short podcast today on an old RCT addressing the utility of hydroxychloroquine (plaquenil) in lupus. It's an oldie but goodie and one that I enjoyed talking about. 

This week we'll discuss the recently published ACR Workforce Study, which estimates a substantial deficit in the workforce by 2030.  We'll consider how dire the situation actually is - checkout the paper itself here. 

This week we'll discuss the recently published ACR Workforce Study, which estimates a substantial deficit in the workforce by 2030.  We'll consider how dire the situation actually is - checkout the paper itself here. 

This week the rheumageddon is postponed (yet again) because I researched a paper about the HScore, a scoring criteria for hemophagocytic lymphohistiocytosis (HLH), during a clinical vignettes presentation for fellowshiop. It made sense to do a podcast about that paper and save the rheumageddon for next week.  Hope y'all enjoy!  Paper can be accessed here. 

Quick podcast tonight reflecting the Rheumatology Journal Club (@RheumJC) discussion! I joined as they discussed the use of abatacept in patients with rheumatoid arthritis who develop ILD.  It's our first observational trial, so it's ripe for critique! Find the original paper here. 

Quick podcast tonight reflecting the Rheumatology Journal Club (@RheumJC) discussion! I joined as they discussed the use of abatacept in patients with rheumatoid arthritis who develop ILD.  It's our first observational trial, so it's ripe for critique! Find the original paper here. 

This week we'll discuss a randomized controlled-ish trial, the RIM study.  It pits rituximab against placebo as well as... rituximab? We'll talk about how their design convincingly demonstrated that ritixan does not have a benefit over placebo for 8 weeks, but may or may not work after that. Find the trial itself here. 

This week we'll discuss a recent trial on mepolizumab - and IL-5 inhibitor - for eosinophilic granulomatosis with polyangiitits.  Find the paper here and be sure to follow us on twitter @JBRheum!